Diphenhydramine HCl oral solution recalled for temperature abuse during manufacturing
McKesson Medical-Surgical is recalling Diphenhydramine HCl oral solution nationwide due to temperature abuse during manufacturing. No illnesses or injuries have been reported.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for manufacturing deviations (temperature abuse) with no reported illnesses or injuries. The hazard is theoretical loss of product efficacy; without reported harm, the score does not exceed 3, warranting Moderate classification.
Plain-English summary
McKesson Medical-Surgical Inc. is recalling Diphenhydramine Hydrochloride oral solution, USP, 25 mg/10 mL, distributed in unit dose cups. The product was distributed nationwide to healthcare facilities.
The recall was initiated due to current Good Manufacturing Practice (cGMP) deviations involving temperature abuse during manufacturing. Temperature abuse can affect the stability and quality of pharmaceutical products.
McKesson Medical-Surgical states that it is unable to identify the specific lot numbers at this time. The company has notified affected customers with information about the dates their product may have been shipped.
Patients and healthcare providers who have this product should contact their pharmacist or healthcare provider for guidance on whether they have affected product and what steps to take.
The recalled product
- Product
- DIPHENHYDRAMINE HYDROCHLORIDE (DIPHENHYDRAMINE HYDROCHLORIDE)
- Brand
- DIPHENHYDRAMINE HYDROCHLORIDE
- Manufacturer
- Mckesson Medical-Surgical Inc. Corporate Office
- Category
- Drug — Oral Solution
- Hazard
- temperature-abuse
- manufacturing-defect
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27